Edition:
United States

Eli Lilly and Co (LLY)

LLY on New York Consolidated

81.06USD
26 Jul 2017
Change (% chg)

$-1.13 (-1.37%)
Prev Close
$82.19
Open
$81.57
Day's High
$81.83
Day's Low
$81.04
Volume
2,045,842
Avg. Vol
3,723,284
52-wk High
$86.72
52-wk Low
$64.18

Select another date:

Tue, Jul 25 2017

Lilly signals long delay for arthritis drug, shares fall

Eli Lilly and Co on Tuesday outlined a likely multi-year delay for its experimental rheumatoid arthritis drug with blockbuster sales potential, and disappointed investors sent its shares down nearly 4 percent.

BRIEF-Eli lilly says seeks external early cancer assets

* Eli Lilly says intends to be more active seeking external preclinical and early stage immuno-oncology assets

Drugmaker Lilly's profit jumps 35 percent

July 25 Eli Lilly and Co on Tuesday reported a 35 percent rise in quarterly profit as the U.S. drugmaker benefited from higher sales of its diabetes treatment Trulicity as well as its psoriasis drug Taltz.

BRIEF-Eli Lilly and Co sets quarterly dividend of $0.52 per share

* Sets quarterly dividend of $0.52per share Source text for Eikon: Further company coverage:

BRIEF-Eli Lilly files supplemental biologics license application with FDA for Taltz

* Eular 2017: Lilly's Taltz (ixekizumab) demonstrated significant improvements in disease signs and symptoms at 24 weeks among patients with active psoriatic arthritis who had prior inadequate response or intolerance to TNF inhibitors

BRIEF-Eli Lilly updates on study data on Jardiance

* Jardiance® (empagliflozin) analysis reinforces established safety profile

BRIEF-Lilly says Jardiance tablets to be studied in chronic kidney disease

* Jardiance® (empagliflozin) tablets to be studied in chronic kidney disease

BRIEF-PeptiDream announces completion of technology transfer of Peptide Discovery Platform System to Lilly

* Says it completes the technology transfer of the Peptide Discovery Platform System (PDPS) to US-based Eli Lilly and Company

BRIEF-United Therapeutics says it entered into first amendment to license agreement with Eli Lilly and company

* United Therapeutics Corp - on May 17, 2017, co entered into first amendment to license agreement with Eli Lilly and company

BRIEF-Eli Lilly and Co files for potential three-part notes offering

* Eli Lilly and Co files for potential three-part notes offering; size undisclosed Source text :(http://bit.ly/2qIKWbH) Further company coverage:

Select another date: